文献速递药物相互作用治疗药物监测与药物基因组学

CYP2D6药物-药物-基因相互作用网络用于精准给药与药物开发

A Comprehensive CYP2D6 Drug-Drug-Gene Interaction Network for Application in Precision Dosing and Drug Development.
PubMed 文献 · Clin Pharmacol Ther · 2025-02-14

本研究构建了一个涵盖CYP2D6药物-基因、药物-药物及药物-药物-基因相互作用的生理药代动力学(PBPK)网络,包含23种化合物,基于30项DGI、45项DDI和7项DDGI研究开发,覆盖32种独特药物组合。所有相互作用类型均显示良好预测性能,并用于计算阿托西汀和美托洛尔的剂量调整,展示模型引导精准给药的临床应用潜力。

要点

  • PBPK网络可预测CYP2D6介导的DDGI,支持临床剂量推荐。
  • 网络覆盖FDA分类的敏感/中度敏感底物及强/弱抑制剂。
  • 模型预测性能良好,AUC与Cmax比值的几何平均倍数误差均较低。

核心结论

  • PBPK建模网络可有效预测CYP2D6介导的DDGI,并支持临床未测试场景的剂量调整。

研究设计与样本

  • 基于PBPK建模构建CYP2D6药物-基因、药物-药物及药物-药物-基因相互作用网络,包含23种化合物。
  • 网络开发基于30项DGI、45项DDI和7项DDGI研究,覆盖32种独特药物组合。

主要发现

  • DDGI、DDI和DGI的AUC比值的几何平均倍数误差分别为1.56、1.38和1.40。
  • DDGI、DDI和DGI的Cmax比值的几何平均倍数误差分别为1.60、1.43和1.29。
  • 网络覆盖FDA指南定义的CYP2D6敏感和中度敏感底物,以及强和弱抑制剂。
  • 对于分析的CYP2D6底物和抑制剂,网络包含了CYP3A4和P-糖蛋白介导的相互作用。

临床怎么用

  • 该网络可用于计算CYP2D6底物(如阿托西汀和美托洛尔)在临床未测试DDGI场景下的剂量调整。
  • PBPK网络为模型引导的精准给药和药物开发中的DDI提交提供框架。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Conducting clinical studies on drug-drug-gene interactions (DDGIs) and extrapolating the findings into clinical dose recommendations is challenging due to the high complexity of these interactions. Here, physiologically-based pharmacokinetic (PBPK) modeling networks present a new avenue for exploring such complex scenarios, potentially informing clinical guidelines and handling patient-specific DDGIs at the bedside. Moreover, they provide an established framework for drug-drug interaction (DDI) submissions to regulatory agencies. The cytochrome P450 (CYP) 2D6 enzyme is particularly prone to DDGIs due to the high prevalence of genetic variation and common use of CYP2D6 inhibiting drugs. In this study, we present a comprehensive PBPK network covering CYP2D6 drug-gene interactions (DGIs), DDIs, and DDGIs. The network covers sensitive and moderate sensitive substrates, and strong and weak inhibitors of CYP2D6 according to the United States Food and Drug Administration (FDA) guidance. For the analyzed CYP2D6 substrates and inhibitors, DD(G)Is mediated by CYP3A4 and P-glycoprotein were included. Overall, the network comprises 23 compounds and was developed based on 30 DGI, 45 DDI, and seven DDGI studies, covering 32 unique drug combinations. Good predictive performance was demonstrated for all interaction types, as reflected in mean geometric mean fold errors of 1.40, 1.38, and 1.56 for the DD(G)I area under the curve ratios as well as 1.29, 1.43, and 1.60 for DD(G)I maximum plasma concentration ratios. Finally, the presented network was utilized to calculate dose adaptations for CYP2D6 substrates atomoxetine (sensitive) and metoprolol (moderate sensitive) for clinically untested DDGI scenarios, showcasing a potential clinical application of DDGI model networks in the field of model-informed precision dosing.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Rüdesheim S, Loer HLH, Feick D, et al. A Comprehensive CYP2D6 Drug-Drug-Gene Interaction Network for Application in Precision Dosing and Drug Development. Clin Pharmacol Ther. 2025. PMID: 39953671. doi:10.1002/cpt.3604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。